SCHEMBL3738809

SCHEMBL3738809

CC(C)(C)OC(=O)N1CC(O)CC1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.53
CHRM1 P11229 1/20 0.53
CHRM3 P20309 1/20 0.53
NR1H2 P55055 1/20 0.41
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
APEX1 P27695 1/20 0.39
BLM P54132 1/20 0.39
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
POLB P06746 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD11B1 P28845 1/20 0.36
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM1A O60341 1/20 0.35
DDB1 Q16531 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18878053 1.00 CHRM2 (0.53) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL6442167 1.00 CHRM2 (0.53) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL6439924 0.87 CHRM2 (0.42) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL16716889 0.83 CHRM2 (0.50) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL26663559 0.83 NR1H2 (0.46) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL24364276 0.82 MEN1 (0.42) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL21452961 0.82 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL433051 0.82 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL3744023 0.82 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2KDM4E
SCHEMBL3744207 0.82 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1325146-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION EIDGENOESSICHE TECH HOCHSCHULE (CH) 2005-12-14 EP claimed
US-20040009562-A1 Process for preparing optically active 4-hydroxy-2-pyrrolidinone and n-substituted 4-hydroxy-2-pyrrolidinones by enzymatic hydroxylation EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2004-01-15 US claimed
EP-1325146-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION Eidgenössiche Technische Hochschule Zürich (CH) 2003-07-09 EP claimed
WO-2002031174-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION EIDGENÖSSICHE TECHNISCHE HOCHSCHULE ZÜRICH (CH) 2002-04-18 WO claimed
EP-1197561-A1 Process for preparing optically active 4-hydroxy-2-pyrrolidinone and N-substituted 4-hydroxy-2-pyrrolidinones by enzymatic hydroxylation Eidgenössische Technische Hochschule Zürich (CH) 2002-04-17 EP claimed
WO-2023130117-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed
EP-3544972-B1 HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS PFIZER (US) 2023-04-26 EP disclosed
CN-110234638-B Heteroaryl phenoxy benzamide KAPPA opioid ligands 辉瑞大药厂 2022-10-21 CN disclosed
EP-3544972-A1 HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS Pfizer Inc (US) 2019-10-02 EP disclosed
US-10316021-B2 Heteroarylphenoxy benzamide kappa opioid ligands PFIZER INC. (US) 2019-06-11 US disclosed
WO-2018096510-A1 HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS PFIZER INC. (US) 2018-05-31 WO disclosed
US-20180148432-A1 HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS PFIZER INC. (US) 2018-05-31 US disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 US disclosed
CN-101415676-A N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same SUMITOMO CHEMICAL CO (JP) 2009-04-22 CN disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 EP disclosed
EP-1325146-B1 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION EIDGENOESSICHE TECH HOCHSCHULE (CH) 2005-12-14 EP disclosed
US-20040009562-A1 Process for preparing optically active 4-hydroxy-2-pyrrolidinone and n-substituted 4-hydroxy-2-pyrrolidinones by enzymatic hydroxylation EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2004-01-15 US disclosed
EP-1325146-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION Eidgenössiche Technische Hochschule Zürich (CH) 2003-07-09 EP disclosed
WO-2002031174-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION EIDGENÖSSICHE TECHNISCHE HOCHSCHULE ZÜRICH (CH) 2002-04-18 WO disclosed
EP-1197561-A1 Process for preparing optically active 4-hydroxy-2-pyrrolidinone and N-substituted 4-hydroxy-2-pyrrolidinones by enzymatic hydroxylation Eidgenössische Technische Hochschule Zürich (CH) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316021-B2 Heteroarylphenoxy benzamide kappa opioid ligands OPRK1, OPRD1, OPRM1 CHRM2 145/4885CHRM1 76/4885CHRM3 243/4885
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 CHRM2 1573/4885CHRM1 622/4885CHRM3 1930/4885
US-20180148432-A1 HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS OPRK1, OPRD1, OPRM1 CHRM2 145/4885CHRM1 76/4885CHRM3 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.